Search

Displaying results 9641 - 9650 of 9731 in total
  1. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.

  2. Drug

    Domiphen

    go.drugbank.com/drugs/DB11594
    Approved

    Domiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.

  3. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...

  4. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    While these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Some patients with advanced urothelial carcinoma experience inadequate therapeutic response from a prior platinum-containing regimen.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  5. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. … Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy.

  6. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.

  8. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such a...

  9. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs). … FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.